EcoDrugPlus

Cholecystokinin B Receptor A

Ensembl ID : ENSOTSG00005046050
Gene Symbol: CCKBRA
1 Cross references
183 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSOTSG00005000528
Gene Symbol: LOC112241278
2 Cross references
185 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSOTSG00005000679
Gene Symbol: LOC112249887
2 Cross references
243 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSOTSG00005008540
Gene Symbol: CETP
3 Cross references
132 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSOTSG00005043006
Gene Symbol: CETP
1 Cross references
131 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSOTSG00005008867
Gene Symbol: CHRM3
1 Cross references
183 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSOTSG00005026876
Gene Symbol: CHRM3
1 Cross references
181 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSOTSG00005015371
Gene Symbol: CHRM3
3 Cross references
182 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSOTSG00005019326
Gene Symbol: CHRM4
3 Cross references
181 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSOTSG00005046957
Gene Symbol: CHRNA3
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSOTSG00005040726
Gene Symbol: CHRNA3
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSOTSG00005011228
Gene Symbol: CHRNA3
1 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).